Tata Chemicals Limited has informed the Exchange regarding Board meeting held on November 01, 2025.
TATACHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tata Chemicals' board approved its Q2 and H1 FY26 results (ended September 30, 2025) along with a plan to raise up to ₹1,500 Crores through Non-Convertible Debentures on a private placement basis. Consolidated revenue from operations fell to ₹3,877 Cr in Q2 from ₹3,999 Cr a year ago, with H1 revenue declining to ₹7,596 Cr from ₹7,788 Cr. Profit attributable to equity shareholders dropped sharply to ₹77 Cr in Q2 (from ₹194 Cr YoY), while H1 PAT was nearly flat at ₹329 Cr vs ₹344 Cr. The company recorded a ₹65 Cr exceptional expense tied to additional closure costs of its UK Lostock soda ash plant. Operating margin compressed to 6.5% in Q2 from 8.5% YoY, though H1 operating margin held steady at ~8.2%. Auditor B S R & Co. LLP issued an unmodified opinion on both consolidated and standalone results.
Soft Q2 print with falling revenue, sharp drop in shareholder profit, and margin compression may weigh on short-term sentiment. However, the ₹1,500 Cr NCD raise signals continued investment capacity, and the specialty products segment showed healthy H1 growth, offering some support to the long-term outlook.